Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) concluded the trading at $0.43 on Wednesday, May 01, with a rise of 15.10% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $0.38 and 5Y monthly beta was reading 0.29. Considering stock’s 52-week price range provides that BCLI hit a high price of $3.34 and saw its price falling to a low level of $0.13 during that period. Over a period of past 1-month, stock came subtracting -39.57% in its value.
In contrast, when we review BCLI stock’s current outlook then short term indicators are assigning it an average of Hold, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of Hold for it.
Digging deeper we become aware of the PEG ratio of the BCLI stock which is currently positioned at 0. It further provides that stock’s current price level is -23.42% away from its 20-day simple moving average and is -9.58% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 41.21 while volatility remained at 20.89% over the past week which changes to 17.36% when measuring it over the past month. Beta is valued at 0.35, while measure of average true range or ATR is currently at 0.09.
Having a second look at Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) provides that stock’s average daily trading volume for 3 months was 1.00 million. Number of outstanding shares of the stock stood at 60.49 million.
The percentage of outstanding shares held by the insiders is 18.91% while it is 5.90% for the institutional holders. Addition of 59.16% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
